Abstract

You have accessJournal of UrologyKidney Cancer: Advanced II1 Apr 2010625 IMMUNOHISTOCHEMICAL STUDY OF C-KIT (CD117) EXPRESSION IN RENAL CELL CARCINOMA Mohamed Youssif and Eman Abdelzaher Mohamed YoussifMohamed Youssif More articles by this author and Eman AbdelzaherEman Abdelzaher More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.961AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Renal cell carcinomas (RCCs) represent a heterogeneous group of tumors with potential prognostic and therapeutic differences. Certain subtypes of RCCs are diagnostically challenging owing to their overlapping histopathological features. Recently, c-KIT (CD117) has come into focus as a potential diagnostic marker of some renal tumors. c-KIT also provides a potentially suitable target for targeted tumor therapy. The present study was designed to investigate the immunohistochemical expression of c-KIT (CD117) in renal cell carcinomas (RCCs) in order to evaluate its diagnostic usefulness as a phenotypic marker and to establish the basis for a new possible therapeutic modality METHODS The expression of c-KIT (CD117) was assessed in 49 patients with renal cell carcinomas using immunohistochemistry. The diagnostic performance of c-KIT expression was evaluated using Receiver Operating Characteristic (ROC) curve analysis RESULTS 49 patients with RCC: clear cell RCC (CRCC): 30 cases (61.22%); chromophobe RCC (ChRCC): 9 cases (18.37%); papillary RCC (PRCC), type I: 5 cases (10.20%); and carcinoma of the collecting ducts of Bellini (CdRCC): 5 cases (10.20%). Overall, 11(22.5%) cases showed c-KIT expression: 2 (6.7%) CRCC, 7 (77.8%) ChRCC, and 2 (40.0%) CdRCC. Among the study group of RCCs, ChRCC had a statistically significant higher frequency (p=.000) and staining score for c-KIT (p=.000) compared to other subtypes of RCC. In addition, only ChRCC showed membranous pattern of c-KIT staining, while other immunoreactive tumors showed cytoplasmic staining (p=.013). c-KIT showed a sensitivity of 77.78% and a specificity of 95% for the diagnosis of ChRCC. The positive likelihood ratio was 15.56 and the negative likelihood ratio was 0.23. The positive predictive value was 45% and the negative predictive value was 98.8%. The relation between c-KIT expression (both the frequency and total staining score) and clinicopathological parameters such as age, sex and stage of tumors was not significant. High grade tumors had a statistically significant higher total score of c-KIT expression (p=.023). CONCLUSIONS c-KIT is frequently and significantly expressed in chromophobe RCC suggesting that it might play a role in its pathogenesis. Immunohistochemical detection of c-KIT expression could be used to aid histological diagnosis of chromophobe RCC with a high sensitivity and specificity. The highest diagnostic accuracy of c-KIT expression in ChRCC is reached at a cutoff point of score > 4 accompanied by membranous pattern of staining. Alexandria, Egypt© 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e245-e246 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mohamed Youssif More articles by this author Eman Abdelzaher More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.